Skip to content

GlobeStar Therapeutics Corp: 10-Q filed 2018-08-01

What GlobeStar Therapeutics Corp reported in its quarterly report filed 2018-08-01 (fiscal Q3 2018): 27 published measures, 70 facts as tagged in accession 0001185185-18-001321.

This filing

Form
10-Q (quarterly report)
Filed
2018-08-01
Fiscal period
fiscal Q3 2018
Accession
0001185185-18-001321 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-30131,441USD
At 2017-09-3024,553USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-30900,840USD
At 2017-09-30648,528USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-30-769,399USD
At 2017-09-30-623,975USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-06-30112,304USD
At 2017-09-3014,100USD
At 2017-06-3011,295USD
At 2016-09-305,845USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-90,985USD91
2017-10-01 to 2018-06-30-596,547USD273
2017-04-01 to 2017-06-30-182,652USD91
2016-10-01 to 2017-06-30-695,468USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-10-01 to 2018-06-30-101,384USD273
2016-10-01 to 2017-06-30-56,550USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-10-01 to 2018-06-301,412USD273
2016-10-01 to 2017-06-300USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2018-04-01 to 2018-06-30242USD91
2017-10-01 to 2018-06-30242USD273
2017-04-01 to 2017-06-300USD91
2016-10-01 to 2017-06-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-10-01 to 2018-06-30201,000USD273
2016-10-01 to 2017-06-3062,000USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-10-01 to 2018-06-30-1,412USD273
2016-10-01 to 2017-06-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-5,778,341USD
At 2017-09-30-5,181,794USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-06-301,412USD
At 2017-09-300USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-10-01 to 2018-06-300USD273
2016-10-01 to 2017-06-30307,720USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-69,720USD91
2017-10-01 to 2018-06-30-240,139USD273
2017-04-01 to 2017-06-30-79,188USD91
2016-10-01 to 2017-06-30-435,890USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-30116,444USD
At 2017-09-3014,850USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-04-01 to 2018-06-3013,219USD91
2017-10-01 to 2018-06-3018,443USD273
2017-04-01 to 2017-06-30103,464USD91
2016-10-01 to 2017-06-30259,578USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-30832,047USD
At 2017-09-30504,855USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-06-304,140USD
At 2017-09-300USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2018-04-01 to 2018-06-3072USD91
2017-10-01 to 2018-06-3072USD273
2017-04-01 to 2017-06-300USD91
2016-10-01 to 2017-06-300USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-3060,627,506shares
At 2017-09-3045,584,067shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-06-301,952,911USD
At 2017-09-301,520,658USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-06-302,912USD
At 2017-09-30-970USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-06-300USD
At 2017-09-300USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2018-06-300USD
At 2017-09-300USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-90,985USD91
2017-10-01 to 2018-06-30-592,665USD273
2017-04-01 to 2017-06-30-181,682USD91
2016-10-01 to 2017-06-30-694,498USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-3069,792USD91
2017-10-01 to 2018-06-30240,211USD273
2017-04-01 to 2017-06-3079,188USD91
2016-10-01 to 2017-06-30435,890USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-10-01 to 2018-06-304,140USD273
2016-10-01 to 2017-06-300USD273

Inspect the source

Entity
GlobeStar Therapeutics Corp / CIK 0001502152
Captured
2026-09-21T17:19:31.788Z
SEC response SHA-256
6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))